Fibrotic Diseases

Anti-fibrotic activity beyond the gut

Expansion Opportunities in Lung and Liver

RvE1 preclinical proof of concept in pulmonary fibrosis and liver injury

Pulmonary Fibrosis

Bleomycin lung fibrosis

Collagen deposition

* 0 20 40 60 80 100 Vehicle BLM BLM + RvE1 Collagen (µg/mg protein)

Lung stiffness

* 0 20 40 60 80 100 Vehicle BLM BLM + RvE1 Elastance (cmH₂O/ml)

RvE1 dosed after fibrosis onset (days 14–20) reduced lung collagen and lung stiffness.

C57BL/6J male mice, n = 6–10 per group, RvE1 4 µg/kg i.p. once daily days 14–20; *p < 0.05 vs BLM. BLM = bleomycin. Antifibrotic effect in this model reported in Ohomori et al., Am J Respir Crit Care Med 2010;181:A3566 (Fukunaga K, ATS 2008); chart data courtesy of Prof. Koichi Fukunaga, Keio University.

Liver Fibrosis

DEN-induced liver injury

Tissue architecture

* 0 1 2 3 Control DEN DEN + RvE1 Architecture score (H&E)

Inflammation

* 0 1 2 3 Control DEN DEN + RvE1 Inflammation score (H&E)

RvE1 preserved hepatic architecture and reduced inflammation in DEN-induced liver injury.

Male Sprague-Dawley rats, DEN i.p. weekly × 4 weeks, RvE1 4 µg/kg i.p. twice weekly, n = 6–9 per group; *p < 0.05 vs DEN. Rodríguez et al., Int J Mol Sci 2020;21:8827.

Partner with Thetis

TP-317 in fibrotic diseases is available for partnering alongside the IBD program.